Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management

about

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management

Item

http://www.wikidata.org/entity/Q58801181

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Homologous recombination defic ...... ts epidemiology and management

@en

Homologous recombination defic ...... ts epidemiology and management

@nl

type

Item

label

Homologous recombination defic ...... ts epidemiology and management

@en

Homologous recombination defic ...... ts epidemiology and management

@nl

prefLabel

Homologous recombination defic ...... ts epidemiology and management

@en

Homologous recombination defic ...... ts epidemiology and management

@nl

P1476

Homologous recombination defic ...... ts epidemiology and management

@en

P2093

Maria Del Pilar Estevez Diz

http://www.w3.org/2001/XMLSchema#string

Renata Rodrigues da Cunha Colombo Bonadio

http://www.w3.org/2001/XMLSchema#string

Rodrigo Nogueira Fogace

http://www.w3.org/2001/XMLSchema#string

Vanessa Costa Miranda

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Homologous recombination in DNA repair and DNA damage tolerance

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Integrated genomic analyses of ovarian carcinoma

Genome maintenance mechanisms for preventing cancer

Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status

Hallmarks of 'BRCAness' in sporadic cancers

P304

e450s

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.6061/CLINICS/2018/E450S

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30133561

http://www.w3.org/2001/XMLSchema#string

P921

P932

6096977

http://www.w3.org/2001/XMLSchema#string